Articles tagged with Messenger Rna
The US government invested at least $337 million in critical research leading to mRNA COVID-19 vaccines before the pandemic, and $31.6 billion during it. These public investments saved millions of lives and have potential to address future pandemics and treat other diseases.
A new method developed by Flatiron Institute researchers can diagnose COVID-19 with near-perfect accuracy, even in asymptomatic patients. The technique monitors the body's molecular response to a viral attack and measures mRNA molecules to identify an immune response.
Researchers estimate transcription error rates in human cells and identify genetic and epigenetic factors responsible for inaccuracies. Inaccurate transcription produces truncated or altered proteins, leading to disease.
A new approach to boosting protein production has been discovered, which could lead to the generation of a universal booster for protein production. The breakthrough centers on Exin21, a sequence that increases mRNA synthesis and stability and protein expression and secretion.
Scientists at the University of Adelaide have constructed the first reference genome for psyllium husk, a versatile plant-derived product used to improve gut health and control blood cholesterol. The discovery will pave the way for improvements to the quality and quantity of psyllium crops.
Researchers developed a new method to quantify the structure and quality of messenger RNA (mRNA) medicines using liquid chromatography, mass spectrometry, and software analysis. The platform can analyze all three key components of mRNA medicines simultaneously, providing unparalleled efficiency in checking for quality.
A recent study published by The BMJ found that COVID-19 vaccination during pregnancy may have benefits for both mother and baby. Two doses of mRNA Covid-19 vaccine were highly effective against delta infection, while two doses against omicron infection showed moderate effectiveness. A third dose during pregnancy also bolstered protecti...
Regulatory T cells suppress self-reactive T cells by controlling protein synthesis, maintaining immune tolerance and preventing autoimmunity. A small molecule inhibitor called RocA also shows promise in mitigating inflammatory responses.
A systematic review and meta-analysis of 17 studies found mRNA COVID-19 vaccination to be associated with lower risks of SARS-CoV-2 infections, severe illnesses, and hospitalizations. While vaccination was linked to higher adverse event rates, the frequency of severe adverse events remained low.
A new approach to gene therapy for inherited blindness uses lipid nanoparticles to deliver mRNA inside the eye, targeting light-sensitive cells and creating proteins that edit vision-harming gene mutations. The technology has shown promising results in animal studies, including mice and nonhuman primates.
Smidt Heart Institute researchers have identified a way to control the natural 'fight back' response of heart cells against RNA therapies, leading to increased effectiveness. By targeting specific microRNAs, they were able to stabilize the heartbeat and boost gene expression.
Researchers discovered that RNA interference, a viral defence mechanism, also prevents overproduction of body's own proteins in intestinal cells, promoting ER quality control. This interplay is crucial for maintaining protein balance and overall intestinal health.
A systematic review of 23 studies found COVID-19 mRNA vaccine-associated myopericarditis is rare in adolescents and young adults with a low incidence rate. The condition generally has favorable early outcomes, but continued follow-up is recommended.
Researchers have developed a polymeric carrier for mRNA vaccines that reduces inflammation and maintains efficiency, potentially offering better cancer treatment options. The new carrier, tested in preclinical studies, shows promise for low-side-effect cancer therapy.
A study published in PLOS Medicine suggests that primary vaccination provides moderate protection against Omicron infection regardless of prior infection history. However, the additional benefit of an original booster dose is unclear in people who have previously experienced COVID-19 infection.
A large study from Argentina found that COVID-19 vaccines remain effective in preventing death in children and adolescents, regardless of the predominant circulating variant. The study's results show that vaccinated children had a 67% reduced risk of death related to COVID-19 infection during the omicron period.
Using an AI, researchers successfully designed synthetic DNA that controls protein production in cells. The technology can speed up the development of vaccines, drugs for severe diseases, and alternative food proteins.
Researchers at Kyoto University discovered METTL16's role in DNA repair and erythropoiesis, a process generating 200 billion new red blood cells daily. Tiny methyl groups on specific mRNAs play a pivotal role in this process, involving mechanisms mediated by RNA-binding proteins.
Researchers identified USP7 as a novel cyclin F-interacting protein that stabilizes cyclin F protein. The study also found that USP7 regulates cyclin F mRNA, with pharmacological inhibition resulting in downregulation of cyclin F mRNA.
A large study found that mRNA vaccines increased myocarditis risk in younger males, especially after the second dose. Absolute rates were low, with higher observed rates compared to expected rates.
Researchers have characterized the functional significance of DDX41 in molecular processes underlying cancer. The study reveals that DDX41 serves crucial functions in transcriptional processes, RNA splicing, and genomic integrity maintenance, which may hold significance in treating hematopoietic malignancies.
The FDA's investigation into its own oversight of clinical trials reveals a concerning lack of surveillance, leaving room for scientific misconduct. Experts argue that the agency should inspect sites more frequently to ensure data quality and integrity.
Scientists at King's College London and the University of Bath have made a groundbreaking discovery about a molecule that plays a crucial role in nerve cell development. The study found that this molecule, known as SNRNP70, is not only present in the nucleus but also in the cytoplasm of nerve cells, where it shapes messenger RNA strand...
Researchers at Hokkaido University developed a novel branched ionizable lipid that significantly increases the efficiency of mRNA delivery by LNPs. The new lipid, CL4F 8-6, was found to enhance protein expression in mice and achieve stable formulations.
A study using mRNA and miRNA expression profiles identified molecular signatures that can differentiate muscle invasive bladder cancer patients who respond to neoadjuvant chemotherapy from those who do not. The research found distinct gene pathways and subtypes associated with response, which may lead to more effective treatment delivery.
A study published in The BMJ found a small increased risk of thrombosis with thrombocytopenia syndrome (TTS) after vaccination against the Covid-19 virus, particularly with adenovirus vaccines. Researchers recommend considering these risks when planning future immunization campaigns and vaccine development.
A retrospective study of 26,000 patients with cirrhosis found that receiving a third dose of the COVID-19 vaccine reduced overall and severe cases by 80% and 100%, respectively. This suggests that a third dose can overcome vaccine hyporesponsiveness in patients with cirrhosis.
A study of 1,199 US essential and frontline workers found that recent mRNA vaccination with 2 or 3 doses before infection with Delta or Omicron variants was associated with attenuated symptoms and viral load. Vaccination status also influenced duration of illness and medical care seeking.
Researchers at Oregon State University have developed a proof-of-principle for a new universal COVID-19 treatment using nanotechnology and messenger RNA. The treatment prompts the production of an enzyme that blocks multiple variants of the SARS-CoV-2 virus from entering cells.
Researchers analyzed 408 patients receiving immune checkpoint inhibitor therapy and found no increased risk of side effects from receiving both immunotherapy and the vaccine. The study supports NCCN's recommendations for COVID-19 vaccination in people with cancer, citing strong protection against severe COVID-19 for all variants.
A research team from Würzburg has discovered a crucial mechanism in cellular growth, showing how cells regulate protein production and keep a reserve of ribosomal proteins to quickly respond to changing conditions. This finding may also shed light on the deregulation of signaling networks in different types of cancer.
A large observational study in Brazil found that mRNA boosting offers considerably better protection against COVID-19 than inactivated CoronaVac boosting, particularly among elderly individuals. The findings have immediate implications for guiding boosting strategies in countries where most of the population received inactivated vaccines.
Researchers have discovered a new pathway for producing telomerase RNA from protein-coding messenger RNA, offering potential innovations in mRNA vaccines and understanding of telomere biology. This finding has implications for reversing cellular aging and extending human lifespan.
A large US population study found that receiving a third dose of an mRNA COVID-19 vaccine reduced the risk of hospitalization due to COVID-19 by approximately 60% compared to receiving only two doses. The association was strongest when measured within three months after booster vaccination.
Researchers at Oregon State University have developed a promising messenger RNA therapy for ovarian cancer, which also shows promise in treating cachexia, a muscle-wasting condition associated with cancer. The treatment uses lipid nanoparticles to deliver mRNA that triggers the production of the follistatin protein within cancer clusters.
A new study by Kyoto University found that Regnase-1 gene expression is low in patients with pulmonary arterial hypertension (PAH), mirroring the pathology of humans. The protein's mRNA degradation leads to PAH inhibition, offering a potential new treatment for heart failure and premature death.
A team of researchers from Ritsumeikan University in Japan has elucidated the mechanism behind the liquid-solid phase transition of FUS protein that leads to ALS. They discovered a new therapeutic target, arginine, which suppresses FUS aggregation and could delay ALS progression.
Researchers have discovered the key components in plant cells that trigger 'wartime' protein production in response to pathogens. This mechanism allows plants to rapidly produce defense proteins while balancing resources between growth and defense, a delicate process that could inform strategies for creating disease-resistant crops.
A study by Osaka University researchers comprehensively analyzed mRNA and microRNA expression patterns in the blood of patients with severe COVID-19, revealing specific mRNAs and microRNAs associated with the immune response pathway. The findings suggest that interferon-β plays a crucial role in COVID-19 severity.
A case-control study found that pregnant women with higher folate levels are at a lower risk of having children with congenital heart disease. The researchers measured red blood cell folate levels and found that those with CHD had significantly lower median levels than those without CHD.
A large Canadian study found no association between Covid-19 vaccination during pregnancy and increased risks of preterm birth or stillbirth. The study analyzed data from over 85,000 births and concluded that vaccination is effective against Covid-19 in pregnant individuals and their newborns.
A large Canadian study published in The Lancet Infectious Diseases journal suggests COVID-19 mRNA vaccines are safe to use in pregnancy. Pregnant women who received the vaccine experienced lower rates of health events post-vaccination compared to non-pregnant vaccinated individuals.
Researchers assessed the safety and adverse events of mRNA COVID-19 vaccines in long-term care residents in Quebec, Canada. No significant adverse events were reported following the third dose, highlighting the vaccine's effectiveness in this vulnerable population.
A case series of six patients reported rare skin reaction complications after receiving the Pfizer/BioNTech COVID-19 mRNA vaccine. The study aims to shed light on these unusual side effects.
A study of 980,000 people found that simultaneous administration of COVID-19 mRNA booster and seasonal influenza vaccines was associated with significant increases in reports of systemic reactions. The study suggests that the combination may lead to more severe adverse events, highlighting the need for further research.
A recent study published by The BMJ confirms previous reports that myocarditis is rare but cases are highest among young males shortly after a second dose of mRNA vaccine, especially Moderna. The risk of myocarditis or pericarditis might be lower when the second dose is given more than 30 days after the first dose.
A new statistical method called Association Plot facilitates the determination and analysis of marker genes in single-cell data. This allows researchers to trace back RNA molecules to their cell of origin, providing insights into cell-type specific genes.
A new imaging technique allows scientists to study mRNA molecules in the brains of living mice, revealing insights into how memories are formed and stored. The research could provide new information about diseases like Alzheimer's and help understand the process of memory generation and retrieval.
A recent study published in the New England Journal of Medicine found that COVID-19 vaccine immunity against new infection appears to wane rapidly, whereas people with a prior-infection were moderately protected from Omicron. Natural immunity provided strong and durable protection against severe illness.
Researchers at IRB Barcelona describe a cellular mechanism that coordinates inflammation resolution, with CPEB4 protein playing a crucial role. This regulation involves the balance between pro-inflammatory TTP and anti-inflammatory CPEB4 proteins.
Researchers at Nagoya University developed a chemical-only process to create customized mRNA vaccines, offering an inexpensive and large-scale production of mRNA. The new method allows for precise molecular design and stable mRNA with improved translational activity.
A single-center study found lower pneumonia frequency and severity in fully vaccinated patients compared to unvaccinated patients. The study included 467 patients who underwent chest CT during hospitalization for symptomatic COVID-19, with significant reductions in pneumonia frequency and severity observed in those fully vaccinated.
A recent study published in The BMJ found that three doses of the same vaccine or a combination of different vaccines work equally well in preventing COVID-19 infections. The research suggests that the number of vaccine doses is key to improving immunity, rather than the combination of vaccine types.
Researchers at Brigham and Women's Hospital studied mRNA vaccine safety in pregnant women, finding no Spike protein expression in placentas. The study provides further evidence of mRNA vaccine safety, supporting expanded vaccination efforts for vulnerable populations.
A study published in AJR found that COVID-19 mRNA vaccination-induced axillary lymphadenopathy resolves after a mean of 97 days. Longer resolution times were observed with Moderna vaccination, receipt of second doses, and thicker cortical thickness at presentation.
Researchers at the University of Cologne investigated UPF3A and UPF3B proteins involved in nonsense-mediated mRNA decay (NMD), a quality control mechanism preventing defective mRNA from being processed into harmful proteins. The study shows that both proteins have partially overlapping functions, enabling fault-tolerant activation of NMD.
State bans on affirmative action policies are associated with lower enrollment of underrepresented minority students in public medical schools. The study found a 5.5 percentage point decrease in enrollment of underrepresented students relative to control schools.
Researchers identified key chemical marks that speed up and slow down gene expression in mRNA, opening new possibilities for genetic therapies. The discovery could lead to targeted protein production with minimal risk, potentially enhancing the effectiveness of mRNA vaccines.
A large-scale study found a link between SARS-CoV-2 mRNA vaccinations and an increased risk of myocarditis, particularly among younger individuals. The study, published in JAMA Cardiology, analyzed data from Denmark, Finland, Norway, and Sweden.
A study of 48,000 individuals found that third-dose vaccination against SARS-CoV-2 with mRNA vaccines was associated with increased reporting of low-severity adverse events. However, there was no significant increase in the reporting of severe adverse events.